BRAF mutations and targeted therapy in unclassified pericytic tumors: insights from genetic analysis and clinical response
Our findings suggest that BRAFi may be a useful therapy for unclassified pericytic tumors. Genetic testing for BRAFV600 mutations and other actionable oncogenic variants should be part of the evaluation for pericytic neoplasms, especially with the currently available targeted drug therapies.
Authors
- Rinat Yacobi
- Ariel Hirschhorn
- Hilla Tabibian‐Keissar
- Gahl Greenberg (ORCID: https://orcid.org/0000-0001-9260-9363)
- Marilena Vered (ORCID: https://orcid.org/0000-0003-1187-2333)
- Iris Barshack (ORCID: https://orcid.org/0000-0001-8216-8963)
- Moshe Leitner (ORCID: https://orcid.org/0000-0003-3648-6447)
- Bella Bielorai (ORCID: https://orcid.org/0000-0003-3066-6439)
- Ninette Amariglio (ORCID: https://orcid.org/0000-0002-2079-6718)
- Michal Yalon (ORCID: https://orcid.org/0000-0001-9832-7068)
- Hana Golan
- G Rechavi
- Amos Toren
- Ran Yahalom
Institutions
- Tel Aviv University (IL)
- Sheba Medical Center (IL)
- Edmond and Lily Safra Children's Hospital (IL)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1186/s12885-025-14595-x
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline
- Novartis Pharma